Dewi Vernerey is a research engineer in epidemiology and biostatistics who received a master’s degree cum laude from Joseph Fourier University (Grenoble, France) with a major in engineering statistics. He defended a PhD in epidemiology and statistics in 2016. His PhD research focused on statistical methodology for risk prediction and prognostic score construction in oncology and kidney transplantation.

    After working for 10 years in Paris at Gustave Roussy institute, Sanofi-Aventis, INSERM Unit 535 and Necker Hospital, he passed in 2009 the national health and medical research institute (INSERM) competitive examination for a research engineer permanent contract.  

    Then, he worked in an epidemiology unit at the Cardiovascular Research Center of Paris (PARCC) located in Georges Pompidou European hospital. In 2013, he decided to join the Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon with his engineer permanent contract. He teaches statistics, data Analysis and methodology in master’s degree and in medical school. 

    Since 2017, he is the head of the “Epidemilogy and Biostatistics” UMQVC’s module and the head of the GERCOR statistical team (INCAS’s labelled data center). He is also a member of the ARCAD foundation and of the HaliodDx’s Scientific Advisory Boards.


Research thematic:

  • Methodology in prognostic research and risk stratification
  • Development and improvement of prognostic and/or predictive tools at population and individual level. 

Main areas of expertise:  

  • Statistics and epidemiology
  • Clinical trial design ans analysis
  • Clinical research
  • Genetic epidemiology (linkage and association analyses)
  • Oncology
  • Solid transplantation (kidney and heart)
  • Cardiology

Main ongoing external collaborations :

  • GERCOR (Multidisciplinary Group in Oncology)
  • Fondation ARCAD (Aide et Recherche en Cancérologie Digestive)
  • AGEO (Association des Gastro-Entérologues Oncologues)
  • FRENCH (Fédération de Recherche EN Chirurgie)

Tools online

  • Prognostic Score and Nomogram to Predict Overall Survival in Locally Advanced Pancreatic Cancer: The PROLAP score 
  • Prognostic Nomogram and Score to Predict Overall Survival in Second Line Chemotherapy for Advanced Pancreatic Cancer: The PROSCAP score 


Main publications

sample

AbstractPURPOSE:The MOSAIC (Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : JCO

sample

AbstractOBJECTIVES:To assess the long term outcomes of transplantation using expanded criteria donors (ECD; donors aged...

Posted by : Dr. Dewi VERNEREY
Journal name : BMJ

sample

AbstractBACKGROUND:The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY
Journal name : Lancet Oncol

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Journal name : JNCI J Natl Cancer Inst

sample

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posted by : Dr. Dewi VERNEREY
Journal name : New England Journal of Medicine

Latest publications

sample

Abstract Background: Baseline prognostic biomarkers stratifying treatment strategies in first-line metastatic...

Posted by : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name :

sample

BACKGROUND:Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a fluoropyrimidine has been standard...

Posted by : Dr. Dewi VERNEREY
Journal name : New England Journal of Medicine

sample

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. We conducted a prospective cohort to describe the prevalence,...

Posted by : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Journal name : Int J Cancer

sample

AbstractBackground: Metastatic signet-ring cell colorectal carcinoma is rare. We analyzed its clinicopathological...

Posted by : Mme. Astrid POZET, Mme. Aurélia MEURISSE, Dr. Dewi VERNEREY
Journal name : Dig Liver Dis

sample

AbstractBackground: Immune checkpoint inhibitors (ICIs) are highly effective in patients with microsatellite...

Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE
Journal name : J Immunother Cancer

sample

AbstractBACKGROUND:About 5% of pancreatic ductal adenocarcinomas are inherited due to a deleterious germline mutation...

Posted by : Dr. Dewi VERNEREY
Journal name : United European Gastroenterol

sample

Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Journal name : JNCI J Natl Cancer Inst

sample

AbstractSmall bowel adenocarcinoma (SBA) is a rare tumour. Large genomic analyses with prognostic assessments are...

Posted by : Dr. Dewi VERNEREY, Mme. Julie HENRIQUES
Journal name : Int J Cancer

sample

ABSTRACT Rationale:The role of circulating antibodies in addition to traditional cardiovascular risk factors in...

Posted by : Dr. Dewi VERNEREY
Journal name : Test

sample

AbstractBackground: A prospective, pooled analysis of six randomised phase 3 trials was done to investigate...

Posted by : Dr. Dewi VERNEREY
Journal name : Lancet Oncol

Latest News

Latest tools

The R package QoLR allows to compute the scoring of main EORTC quality of life questionnaires and to perform the...

Posted by : , Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN,

The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for...

Posted by : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY

Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY

Currently, the management of advanced pancreatic cancer patients is complex in second-line chemotherapy according to the...

Posted by : Dr. Angélique VIENOT, Dr. Dewi VERNEREY

2015-2022 © Copyright - UMQVC.org

Website by Pearlweb